197 related articles for article (PubMed ID: 22498210)
1. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
[TBL] [Abstract][Full Text] [Related]
2. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
Cooke EW; Shrieve DC; Tward JD
Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
[TBL] [Abstract][Full Text] [Related]
3. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
4. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
[TBL] [Abstract][Full Text] [Related]
5. Contemporary evaluation of the D'amico risk classification of prostate cancer.
Hernandez DJ; Nielsen ME; Han M; Partin AW
Urology; 2007 Nov; 70(5):931-5. PubMed ID: 18068450
[TBL] [Abstract][Full Text] [Related]
6. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
7. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
9. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
10. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
11. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
12. Frequency and determinants of missing data in clinical and prognostic variables recently added to SEER.
Kim HM; Goodman M; Kim BI; Ward KC
J Registry Manag; 2011; 38(3):120-31. PubMed ID: 22223054
[TBL] [Abstract][Full Text] [Related]
13. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?
Chamie K; Oberfoell S; Kwan L; Labo J; Wei JT; Litwin MS
Urology; 2013 May; 81(5):949-55. PubMed ID: 23477756
[TBL] [Abstract][Full Text] [Related]
14. Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.
Scholz MC; Groom MK; Kaddis AJ; Strum SB; Jennrich RI; Bahn DK; Chang PJ; Becker LK; Lam RY
Prostate; 2013 Jan; 73(1):83-8. PubMed ID: 22753276
[TBL] [Abstract][Full Text] [Related]
15. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.
Gabriele D; Jereczek-Fossa BA; Krengli M; Garibaldi E; Tessa M; Moro G; Girelli G; Gabriele P;
Radiat Oncol; 2016 Feb; 11():23. PubMed ID: 26911291
[TBL] [Abstract][Full Text] [Related]
16. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
17. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
18. [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?].
Misrai V; Do C; Lhez JM; Elman B; Latorzeff I; Portalez D; Grosclaude P
Prog Urol; 2012 May; 22(5):273-8. PubMed ID: 22515923
[TBL] [Abstract][Full Text] [Related]
19. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease.
Reese AC; Cooperberg MR; Carroll PR
J Urol; 2010 Jul; 184(1):114-9. PubMed ID: 20478578
[TBL] [Abstract][Full Text] [Related]
20. Disproportionate presentation of high risk prostate cancer in a safety net health system.
Porten SP; Richardson DA; Odisho AY; McAninch JW; Carroll PR; Cooperberg MR
J Urol; 2010 Nov; 184(5):1931-6. PubMed ID: 20846693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
